ATE395081T1 - Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum - Google Patents

Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum

Info

Publication number
ATE395081T1
ATE395081T1 AT97936112T AT97936112T ATE395081T1 AT E395081 T1 ATE395081 T1 AT E395081T1 AT 97936112 T AT97936112 T AT 97936112T AT 97936112 T AT97936112 T AT 97936112T AT E395081 T1 ATE395081 T1 AT E395081T1
Authority
AT
Austria
Prior art keywords
inhibiting
growth
cell activation
antibodies
cd2a
Prior art date
Application number
AT97936112T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Ruth Kaplan
Thomas Kieber-Emmons
Christina Postema
Mary White-Scharf
Original Assignee
Biotransplant Inc
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Univ Catholique Louvain filed Critical Biotransplant Inc
Application granted granted Critical
Publication of ATE395081T1 publication Critical patent/ATE395081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97936112T 1995-06-07 1997-07-18 Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum ATE395081T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,281 US5817311A (en) 1993-03-05 1995-06-07 Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
PCT/US1997/012645 WO1999003502A1 (en) 1995-06-07 1997-07-18 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
ATE395081T1 true ATE395081T1 (de) 2008-05-15

Family

ID=26792646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936112T ATE395081T1 (de) 1995-06-07 1997-07-18 Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum

Country Status (10)

Country Link
US (1) US5817311A (de)
EP (1) EP1003552B1 (de)
AT (1) ATE395081T1 (de)
AU (1) AU754185B2 (de)
CA (1) CA2295604C (de)
DE (1) DE69738692D1 (de)
DK (1) DK1003552T3 (de)
ES (1) ES2307301T3 (de)
HK (1) HK1025738A1 (de)
WO (1) WO1999003502A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US6849258B1 (en) * 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
EE200100123A (et) * 1998-08-31 2002-06-17 Biogen, Incorporated CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
US6541611B1 (en) * 1999-06-18 2003-04-01 Universite Catholique De Louvain LO-CD2b antibody
US20040170635A1 (en) * 2001-02-01 2004-09-02 Vaishnaw Akshay K. Methods for treating or preventing skin disorders using cd2-binding agents
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
US7858095B2 (en) * 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
EP1506236B1 (de) * 2002-05-22 2013-01-23 ESBATech - a Novartis Company LLC Immunglobulinrahmen mit verbesserter stabilität im intrazellulären raum und verfahren zu deren identifizierung
CA2555144A1 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
WO2005112568A2 (en) * 2004-05-04 2005-12-01 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
WO2005115436A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EP2334783B1 (de) * 2008-09-02 2016-06-22 Pluristem Ltd. Adhärente zellen aus plazentagewebe und verwendung davon in der therapie
US20200407440A1 (en) 2019-04-24 2020-12-31 Magenta Therapeutics, Inc. Amatoxin antibody-drug conjugates and uses thereof
WO2021005009A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP4175668A1 (de) 2020-07-06 2023-05-10 iOmx Therapeutics AG Igv von igsf11 (vsig3) bindende antikörper und verwendungen davon
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991001752A1 (en) * 1989-07-27 1991-02-21 Fred Hutchinson Cancer Research Center Immunosuppressive monoclonal antibodies, hybridomas and methods of transplantation
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
PT687300E (pt) * 1993-03-05 2002-03-28 Univ Catholique Louvain Anticorpo lo-cd2a e sua utilizacao para a inibicao da activacao e proliferacao de celulas-t

Also Published As

Publication number Publication date
DK1003552T3 (da) 2008-08-25
EP1003552A4 (de) 2002-10-02
CA2295604C (en) 2008-09-30
US5817311A (en) 1998-10-06
DE69738692D1 (de) 2008-06-26
EP1003552B1 (de) 2008-05-14
CA2295604A1 (en) 1999-01-28
HK1025738A1 (en) 2000-11-24
EP1003552A1 (de) 2000-05-31
WO1999003502A1 (en) 1999-01-28
AU3886297A (en) 1999-02-10
ES2307301T3 (es) 2008-11-16
AU754185B2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
DE68925226T2 (de) Monoklonale Antikörper
EP0313378A3 (de) Methoden und Zusammensetzungen für vorübergehende Elimination von humoralen immunen Antikörpern
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
Kim et al. Incorporation of a ligand peptide for immune inhibitory receptor LAIR‐1 on biomaterial surfaces inhibits macrophage inflammatory responses
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE520834T1 (de) PP14 oder Antikörper gegen PP14 enthaltende pharmazeutische Zusammensetzung zur Behandlung von Immunsystemstörungen.
DE69221605T2 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
NO941347L (no) Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003552

Country of ref document: EP